lungs. MALT lymphoma is divided into two categories: gastric, which develops in the stomach and is the most common site, and nongastric, which develops outside of the stomach.
In many cases of MALT lymphoma, the patient has a previous medical history of chronic infection, inflammation, or autoimmune disorders at the affected organ. For example, Helicobacter pylori (H. pylori), a microbial pathogen linked to chronic gastritis, has been associated with a significant proportion of patients with gastric MALT lymphoma.
Nodal MZL (sometimes called monocytoid B-cell lymphoma)
occurs within the lymph nodes and accounts for about 10 percent of all MZL cases. 
Treatment Options
Treatment selection for a patient with MZL depends on the type, the stage and location of the disease, the patient's age and overall health, and any lymphoma-related signs or symptoms.
Gastric MALT
Since gastric MALT lymphoma is often the result of an infection with H. pylori, the initial treatment is antibiotic therapy, usually combined with proton pump inhibitors (PPIs), which is typically given for two weeks. PPIs reduce the production of stomach acid to help prevent or heal ulcers. In about 90 percent of cases, these lymphomas 
Nodal MZL
Because nodal MZL is most often a slow-growing disease, physicians may adopt a "watch and wait" approach until symptoms appear. When treatment is necessary, options include radiation therapy, chemotherapy and/or immunotherapy, and other treatments commonly used in other types of slow-growing lymphomas, such as follicular lymphoma.
Splenic MZL
Treatment is not always immediately necessary for splenic MZL.
When treatment is deemed appropriate, several options exist.
Some patients may receive a splenectomy (surgical removal of the spleen); patients ineligible for surgery may receive low-dose Helpline: (800) 500-9976 helpline@lymphoma.org
Getting the Facts
radiation of the spleen. Other patients may be given rituximab, a monoclonal antibody, with or without chemotherapy. In some cases, because of the association of this type of lymphoma with HCV, interferon with or without antiviral therapy may be given to patients who show evidence of HCV infection.
Treatments Under Investigation
Several new drugs and drug combinations are being studied in clinical trials for MZL and other slow-growing lymphomas, including:
• Bendamustine (Treanda)
• 
Clinical Trials
Clinical trials are crucial in identifying effective drugs and determining optimal doses for patients 
Resources
LRF offers a wide range of resources that address treatment options, the latest research advances, and ways to cope with all aspects of lymphoma and MZL, including our award-winning mobile app.
LRF also provides many educational activities, from in-person meetings to teleconferences and webcasts for people with MZL, as well as disease-specific websites, videos, and e-Updates for current lymphoma information and treatment options. For more information about any of these resources, visit our website at www.lymphoma.org, or contact the LRF Helpline at (800) 500-9976 or helpline@lymphoma.org. 
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